Llwytho...

A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms

BACKGROUND: Ibrutinib is an orally administered inhibitor of Bruton’s tyrosine kinase (Btk). Preclinical data suggest that mast cells are recruited within neuroendocrine neoplasms (NENs) where they stimulate angiogenesis and tumor growth. Ibrutinib inhibits mast cell degranulation and has been assoc...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuroendocrinology
Prif Awduron: Al-Toubah, Taymeyah, Schell, Michael J., Cives, Mauro, Zhou, Jun-Min, Soares, Heloisa P., Strosberg, Jonathan R.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2019
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7771542/
https://ncbi.nlm.nih.gov/pubmed/31357193
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000502383
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!